Chronic kidney disease, plasma lipoproteins, and coronary artery calcium incidence: The multi-ethnic study of atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 3, 2013, Pages 652-658

  Lamprea Montealegre, Julio A ^a   McClelland, Robyn L ^b   Astor, Brad C ^c   Matsushita, Kunihiro ^d   Shlipak, Michael ^e   De Boer, Ian H ^f   Szklo, Moyses ^d  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

atherosclerosis; chronic kidney disease; coronary artery calcium; lipoproteins

Indexed keywords

ANTILIPEMIC AGENT; CALCIUM; CHOLESTEROL; CYSTATIN C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY CALCIUM SCORE; DISEASE ASSOCIATION; ETHNICITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL;

AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CYSTATIN C; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; KIDNEY; LIPOPROTEINS; MALE; MIDDLE AGED; NONLINEAR DYNAMICS; ODDS RATIO; PRINCIPAL COMPONENT ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TRIGLYCERIDES; UNITED STATES; VASCULAR CALCIFICATION;

EID: 84874351509     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300624     Document Type: Article

References (33)

1. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375: 2701-2081.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
3. Ix JH, Katz R, Kestenbaum B, Fried LF, Kramer H, Stehman-Breen C, Shlipak MG. Association of mild to moderate kidney dysfunction and coronary calcification. J Am Soc Nephrol. 2008;19:579-585.
4. Bui AL, Katz R, Kestenbaum B, de Boer IH, Fried LF, Polak JF, Wasserman BA, Sarnak MJ, Siscovick D, Shlipak MG. Cystatin C and carotid intima-media thickness in asymptomatic adults: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis. 2009;53:389-398.
5. Krasnikov S.V. Causality violation and paradoxes. Physical Review. 1997; 55: 3427-3430.
6. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet. 1986;2:933-936.
7. McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, Steyn K, Sanderson JE, Hasani M, Volkova E, Kazmi K, Yusuf S; INTERHEART study investigators. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372:224-233.
8. Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. Lancet. 2007; 370: 1829-1839.
9. Catapano AL, Reiner Z, De Backer G, et al.; European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217:3-46.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001; 285:2486-2497.
11. Musunuru K, Orho-Melander M, Caulfield MP, Li S, Salameh WA, Reitz RE, Berglund G, Hedblad B, Engström G, Williams PT, Kathiresan S, Melander O, Krauss RM. Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk. Arterioscler Thromb Vasc Biol. 2009;29:1975-1980.
12. Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb. 1992;12:1496-1502.
13. de Boer IH, Astor BC, Kramer H, Palmas W, Seliger SL, Shlipak MG, Siscovick DS, Tsai MY, Kestenbaum B. Lipoprotein abnormalities associated with mild impairment of kidney function in the multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol. 2008;3:125-132.
14. Bild DE, Bluemke DA, Burke GL, et al. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol. 2002;156:871-881.
15. Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, Rossert J, Van Lente F, Bruce RD III, Zhang YL, Greene T, Levey AS. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis. 2008;51:395-406.
16. Goff DC Jr, Bertoni AG, Kramer H, Bonds D, Blumenthal RS, Tsai MY, Psaty BM. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation. 2006;113:647-656.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
18. Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab. 2002;48:171-180.
19. Carr JJ, Nelson JC, Wong ND, McNitt-Gray M, Arad Y, Jacobs DR Jr, Sidney S, Bild DE, Williams OD, Detrano RC. Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. Radiology. 2005;234:35-43.
20. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15:827-832.
21. Kronmal RA, McClelland RL, Detrano R, Shea S, Lima JA, Cushman M, Bild DE, Burke GL. Risk factors for the progression of coronary artery calcification in asymptomatic subjects: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2007;115:2722-2730.
22. Anderson T. Asymptotic theory for principal component analysis. Annals of Mathematical Statistics. 1963;34:122-148.
23. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702-706.
24. McClelland RL, Kronmal RA, Haessler J, Blumenthal RS, Goff DC Jr. Estimation of risk factor associations when the response is influenced by medication use: an imputation approach. Stat Med. 2008;27:5039-5053.
25. Lee TC, O'Malley PG, Feuerstein I, Taylor AJ. The prevalence and severity of coronary artery calcification on coronary artery computed tomography in black and white subjects. J Am Coll Cardiol. 2003;41:39-44.
26. de Boer IH, Kestenbaum B, Shoben AB, Michos ED, Sarnak MJ, Siscovick DS. 25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J Am Soc Nephrol. 2009;20:1805-1812.
27. Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, James MT, Hemmelgarn BR; Alberta Kidney Disease Network. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380:807-814.
28. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238-248.
29. Fellström BC, Jardine AG, Schmieder RE, et al.; AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395-1407.
30. Baigent C, Landray MJ, Reith C, et al.; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181-2192.
31. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP; Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107:2409-2415.
32. Bossé Y, Chagnon YC, Després JP, Rice T, Rao DC, Bouchard C, Pérusse L, Vohl MC. Genome-wide linkage scan reveals multiple susceptibility loci influencing lipid and lipoprotein levels in the Quebec Family Study. J Lipid Res. 2004;45:419-426.
33. Kristiansson K, Perola M, Tikkanen E, et al. Genome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits. Circ Cardiovasc Genet. 2012;5:242-249.